Spots Global Cancer Trial Database for relapsed ovarian cancer

Every month we try and update this database with for relapsed ovarian cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer	NCT04339140	Ovarian Cancer	Zafirlukast	18 Years -	Beth Israel Deaconess Medical Center
An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer	NCT00738699	Ovarian Cancer	MORAb-003 (farl... 0.9% Saline Paclitaxel	18 Years - 99 Years	Morphotek
Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer	NCT04339140	Ovarian Cancer	Zafirlukast	18 Years -	Beth Israel Deaconess Medical Center
Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status	NCT01690598	Ovarian Cancer	Veliparib Topotecan	18 Years -	Vejle Hospital
A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients	NCT04517357	Relapsed Ovaria...	Fluzoparib+Apat... Fluzoparib Fluzoparib+Apat...	18 Years -	Jiangsu HengRui Medicine Co., Ltd.
Reprab Study: PLD + Trabectedin Rechallenge	NCT04887961	Relapsed Ovaria...	PLD and Trabect...	18 Years -	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial	NCT05607329	Relapsed Ovaria...	Secondary cytor... Chemotherapy	18 Years - 70 Years	Women's Hospital School Of Medicine Zhejiang University
Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse	NCT00849667	Ovarian Cancer	Farletuzumab Carboplatin Taxane Farletuzumab-ma...	18 Years -	Morphotek
Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer	NCT05080556	Ovarian Cancer Relapsed Ovaria... Fallopian Tube ... Peritoneal Canc... Endometrioid Ca... High Grade Sero... Ovary Cancer	Carboplatin	18 Years -	University College, London
Reprab Study: PLD + Trabectedin Rechallenge	NCT04887961	Relapsed Ovaria...	PLD and Trabect...	18 Years -	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy	NCT01874353	Platinum Sensit... BRCA Mutated Relapsed Ovaria... Following Compl...	Olaparib 300mg ... Placebo to matc...	18 Years - 130 Years	AstraZeneca
Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients	NCT02825420	Relapsed Ovaria...	trabectedin	18 Years -	PharmaMar
A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer	NCT04999605	Ovarian Neoplas... Recurrent Ovari... Relapsed Ovaria... Ovarian Cancer	AK112 low dose AK112 medium do... AK112 high dose	18 Years - 75 Years	Akeso
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer	NCT00090610	Ovarian Cancer	Docetaxel Carboplatin	18 Years -	Duke University
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer	NCT00090610	Ovarian Cancer	Docetaxel Carboplatin	18 Years -	Duke University
Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status	NCT01690598	Ovarian Cancer	Veliparib Topotecan	18 Years -	Vejle Hospital
Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial	NCT05607329	Relapsed Ovaria...	Secondary cytor... Chemotherapy	18 Years - 70 Years	Women's Hospital School Of Medicine Zhejiang University
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib	NCT02873962	Peritoneal Canc... Ovarian Cancer Fallopian Tube ...	Bevacizumab Nivolumab Rucaparib	18 Years -	Dana-Farber Cancer Institute
A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer	NCT04999605	Ovarian Neoplas... Recurrent Ovari... Relapsed Ovaria... Ovarian Cancer	AK112 low dose AK112 medium do... AK112 high dose	18 Years - 75 Years	Akeso
Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial	NCT05607329	Relapsed Ovaria...	Secondary cytor... Chemotherapy	18 Years - 70 Years	Women's Hospital School Of Medicine Zhejiang University
Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy	NCT03534453	Relapsed Ovaria... Following Compl... Platinum Sensit...	Olaparib 300mg ...	18 Years - 130 Years	AstraZeneca
Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer	NCT04339140	Ovarian Cancer	Zafirlukast	18 Years -	Beth Israel Deaconess Medical Center
A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients	NCT04517357	Relapsed Ovaria...	Fluzoparib+Apat... Fluzoparib Fluzoparib+Apat...	18 Years -	Jiangsu HengRui Medicine Co., Ltd.
An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer	NCT00738699	Ovarian Cancer	MORAb-003 (farl... 0.9% Saline Paclitaxel	18 Years - 99 Years	Morphotek

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: